ModifiedCareSourcePolicy N/A

Intravenous Immune Globulin (IVIG) utilization

Defines prior authorization, clinical criteria, and dosing guidance for coverage of intravenous immune globulin products for members when used for FDA-approved and selected off-label indications. Applies to providers prescribing IVIG to CareSource members in North Carolina.

Policy Summary

PayerCareSource

PolicyIntravenous Immune Globulin (IVIG) utilization

Policy CodePolicy N/A

Change TypeAnnual revision with added indications and dosing updates

Effective DateNov 6, 2024

Next Review DateNov 6, 2024

Key ActionPrior authorization is required; submit documentation supporting diagnosis, relevant labs (age‑adjusted IgG, troughs, CK), prior therapy trials or contraindications, and prescriber specialty to obtain approval.

SourceLink

POLICY UPDATE CHANGES

Aquaporin-4 Immunoglobulin Antibody (AQP4-IgG)-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD); Immune-Mediated Necrotizing Myopathy; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) were added as conditions of approval.

Duration of approval for initial therapy for Immune Thrombocytopenia (ITP) was changed from 1 year to 3 months and continuation/retreatment criteria were added.

CIDP maintenance and loading dosing schedules were updated (details on divided dosing days and maintenance dosing days revised).

Specific product additions: Alyglo, Yimmugo, and other branded IVIG products were added with same criteria as other immune globulin products.

Primary Immunodeficiencies: clarified that molecular testing is a type of genetic testing.

13+IVIG products listed by brand name

YearPrimary immunodeficiency initial approval period

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Medical Necessity

inv-02: Primary immunodeficiency — covered when ONE of the primary immunodeficiency pathways is met

Covered when ONE of the primary immunodeficiency pathways is met

Primary immunodeficiency: Patient has diagnosis of congenital agammaglobulinemia, X-linked agammaglobulinemia, absence of B‑cells, Wiskott‑Aldrich, ataxia telangiectasia, DiGeorge, severe combined immunodeficiency, Hyper‑IgM syndromes, or other confirmed primary immune deficiency OR common variable immunodeficiency/unspecified hypogammaglobulinemia with significant hypogammaglobulinemiaage‑adjusted IgG below normal range or confirmed by genetic/molecular testing

Initial therapy requires impaired antibody response or recurrent infections and prescriber specialty

Initial therapy for CVID/related hypogammaglobulinemia: Pretreatment IgG below normal (age‑adjusted) AND impaired antibody response OR recurrent infectionspretreatment IgG below normal range

Prescriber may exempt vaccination testing if delay would be harmful

Continuation therapy: Patient currently receiving IVIG and prescriber documents ongoing benefit (e.g., increased IgG troughs or reduced infections)prescriber assessment

Must be prescribed by or in consultation with appropriate specialists (allergist, immunologist, ENT, pulmonologist, infectious diseases)

inv-03: Secondary immunodeficiency (hematologic) — covered when diagnosis-specific AND/OR continuation criteria are met

Covered when the following diagnosis-specific AND/OR continuation criteria are met

B-cell CLL prevention: Initial therapy: IgG <= 600 mg/dL (6.0 g/L) OR history of recurrent infections; prescribed by or in consultation with an oncologist, hematologist, or infectious diseases physician; initial approval 4 months; continuation if positive responseIgG <= 600 mg/dL

Maintenance dosing may be adjusted to maintain trough >500 mg/dL

Hematologic neoplasm-associated hypogammaglobulinemia: IgG < 600 mg/dL AND recurrent or severe infections or high infection risk per prescriber AND prescribed by/with oncology/hematology/infectious disease/immunologyIgG < 600 mg/dL

Initial approvals typically 6 months; continuation based on response (maintain IgG trough per prescriber)

inv-04: Neurologic autoimmune disorders — covered when diagnosis is supported by objective testing and timing/therapy trial requirements are met

Covered when diagnosis is supported by objective testing and timing/therapy trial requirements are met

CIDP initial therapy: Electrodiagnostic studies support CIDP diagnosis AND medication prescribed by or in consultation with a neurologistelectrodiagnostic support

Initial approval 3 months; dosing examples include 2 g/kg loading then maintenance 1 g/kg every ~3 weeks with maximum 2 g/kg per course; continuation if significant improvement

Guillain‑Barré Syndrome (GBS): IVIG initiated within 2 weeks (no more than 4 weeks) after onset OR treatment‑related fluctuation with initial response; prescribed by/with neurologisttiming within 2–4 weeks

Approve 1 month (one course); dosing 2 g/kg divided over 2–5 days

Multifocal Motor Neuropathy (MMN):

inv-05: Dermatologic and inflammatory myopathies — covered when systemic corticosteroid and immunosuppressive agent trials have failed or are contraindicated, or disease is rapidly progressive

Covered when systemic corticosteroid and immunosuppressive agent trials have failed or are contraindicated, or disease is rapidly progressive

Pemphigus/Pemphigoid initial therapy: Patient has tried systemic corticosteroid AND an immunosuppressive agent OR these are contraindicated, OR disease is too severe/rapid to await effectprior therapy trial or contraindication

Initial approval generally 6 months; typical dosing 2 g/kg divided over multiple days every 3–4 weeks; continuation based on response

Dermatomyositis/Polymyositis (including immune‑mediated necrotizing myopathy): Elevated CK (e.g., >1,000 IU/L) OR supportive testing (muscle biopsy, EMG, MRI) AND patient has tried systemic corticosteroid and an immunosuppressive agent OR these are contraindicatedelevated CK and prior therapy trial

Initial approval 6 months; prescribing neurologist or rheumatologist involvement required; dosing examples include 2 g/kg loading then maintenance regimens

inv-06: Transplant-related and post-transplant infection prevention — covered with specialist involvement and transplant-center protocols where applicable

Covered with specialist involvement and transplant‑center protocols where applicable

Antibody‑mediated rejection / Desensitization: Prescribed by or in consultation with a physician affiliated with a transplant center; dosage may follow center protocoltransplant center involvement

Approve up to 1 year; dosing per protocol or up to 2 g/kg/month (e.g., 400 mg/kg daily x5 days)

Hematopoietic Cell Transplantation (HCT) to prevent infection: Patient had HCT within previous year AND IgG threshold criteria or high infection risk per prescribermaintain IgG > 400 mg/dL

Initial therapy approve 3 months with adjustments to maintain IgG >400 mg/dL; continuation up to 6 months if responding; dosing differs by age and time since HCT

inv-07: Other supportive evidence indications — covered when indication-specific clinical and timing criteria are met and prescriber specialty is appropriate

Covered when indication‑specific clinical and timing criteria are met and prescriber specialty is appropriate

Immune Thrombocytopenia (ITP): Adult patient tried systemic corticosteroid OR corticosteroid contraindicated AND urgent need to increase platelet count OR prescribed/consulted with hematologisttrial of corticosteroid or documented contraindication

Initial approvals generally 3 months (6 months for pregnant patients); dosing examples include up to 1 g/kg for 1–2 days or 0.4 g/kg daily x5 days; continuation based on response

Kawasaki disease: Prescribed by or in consultation with pediatric cardiologist or pediatric infectious diseases physicianpediatric specialist involvement

Approve 3 months; dosing up to 2 g/kg single dose or divided; may repeat if clinically indicated

MS acute severe relapse:

inv-09: Multiple Sclerosis — Acute Severe Exacerbation — covered when ALL criteria are met for one course

Covered when ALL criteria are met for one course.

MS acute relapse: Patient has not responded to or had significant adverse reaction to systemic corticosteroids OR plasma exchange OR systemic corticosteroid is contraindicated; AND patient is on or will start maintenance MS therapy; AND prescribed by or in consultation with a neurologist or MS specialist

Approve for 1 month to allow one course; dosing options include 0.4 g/kg daily for 5 days or single 1 g/kg IV; dosing up to 2 g/kg/month possible

inv-10: Neurologic and Hematologic Indications with Specialist Involvement — covered when listed condition-specific criteria and specialist prescriptions are met

Covered when listed condition‑specific criteria and specialist prescriptions are met.

Neurologic and Hematologic indications with specialist involvement: Conditions such as LEMS, multiple myeloma‑associated infections, CAR‑T/B‑cell therapy‑related hypogammaglobulinemia, MOGAD, Guillain‑Barré, and others

Each indication requires condition‑specific prior therapies/trials or documentation of contraindications, specialist prescribing/consultation, and response criteria for continuation approvals; examples: LEMS requires prior symptomatic therapy, MOGAD and NMOSD require positive antibody testing

inv-11: Post-Exposure Prophylaxis and Infection-related Uses — single-dose prophylactic uses covered when exposure and susceptibility criteria are met

Single‑dose prophylactic uses are covered when exposure and susceptibility criteria are met.

Measles post‑exposure (passive immunization): Pregnant patients or immunocompromised patients exposed to measles who cannot readily show evidence of immunity; one‑time IVIG 0.4 g/kg

Approve for 1 day to allow single dose

Varicella/tetanus post‑exposure or treatment: One‑time IVIG when varicella or tetanus immune globulin is unavailable or cannot be administered

Dosing examples include 0.2–0.4 g/kg or 0.4 g/kg given one time; approve for single dose

Parvovirus B19 in immunodeficient patients: Initial therapy approvals when immunodeficiency present and prescriber is infectious disease/hematology/transplant specialist

Approve for initial periods (e.g., 2 months); dosing regimens allowed include 0.4–0.5 g/kg daily x5 days, 2 g/kg over 2–5 days, or 0.4 g/kg every 4 weeks

inv-12: Fetal‑neonatal Alloimmune Thrombocytopenia — covered when prescribed by/with hematologist or obstetrician for pregnant mother or newborn

Covered when prescribed by or in consultation with a hematologist or obstetrician for pregnant mother or newborn.

FNAIT: Fetal‑neonatal alloimmune thrombocytopenia: approve when mother or newborn is prescribed IVIG by or in consultation with a hematologist or obstetrician

Approve for 6 months; dosing options for the mother include 1–2 g/kg IV weekly or twice weekly or as specified by prescriber

inv-13: Selected revised/added coverage criteria — recent additions/changes to conditions of approval

Conditions newly added or revised in recent history entries

Newly added conditions of approval: Aquaporin‑4 IgG‑positive NMOSD OR Immune‑mediated necrotizing myopathy OR MOGAD

These conditions were added to the list of conditions eligible for IVIG per the policy revision.

ITP initial therapy duration change: Initial therapy for Immune Thrombocytopenia (ITP) approval duration changed to 3 months (from 1 year)3 months

Continuation and retreatment criteria were added per history; see policy for specifics

CIDP dosing revisions: CIDP loading and maintenance dosing schedules were revised (loading dose and maintenance dose frequency/days updated)

See history and CIDP criteria for updated divided dosing day counts and maintenance dosing days

IVIG products are used for many off‑label indications, and the supporting evidence for those uses is often low‑level (case reports, open series, cohort studies). Because of this variable evidence base, the policy states that IVIG is usually indicated only if standard approaches have failed, become intolerable, or are contraindicated and that use for off‑label indications should be reserved for those circumstances.

Within the provided policy sections there are no explicit exclusions stated for IVIG beyond the indication‑specific criteria; other parts of the full policy document may contain additional exclusion statements or lists.

The policy lists numerous conditions for which coverage of IVIG is not recommended. Examples include: adrenoleukodystrophy; Alzheimer’s disease; amyotrophic lateral sclerosis; asthma; atopic dermatitis; autism; complex regional pain syndrome; Crohn’s disease; cystic fibrosis; immunotherapy for diabetes mellitus; fibromyalgia; use as an adjunct in in‑vitro fertilization (IVF); POEMS syndrome; recurrent spontaneous pregnancy loss in specified contexts; and selective IgA deficiency when it is the sole immunologic abnormality. The policy states coverage is also not recommended for circumstances not described in the recommended authorization criteria.

The policy history documents a change: Chronic Fatigue Syndrome was removed from the list of conditions not recommended for approval, indicating it is no longer explicitly listed among those discouraged uses.

Requests that do not meet the policy’s specified clinical criteria, dosing, or documentation requirements (including unsupported dosing or indications without adequate documentation) are subject to review and may be denied. The policy also notes that dosing outside established policy will be considered case‑by‑case and may be denied if not justified.

The provided excerpts do not include a comprehensive list of all conditions considered not medically necessary; the policy notes that additional not‑medically‑necessary (NMN) conditions may appear elsewhere in the full document.

The policy’s rationale for non‑coverage is that IVIG is not medically necessary for indications where the evidence does not demonstrate clinical benefit. The document explicitly cites multiple conditions with insufficient or negative evidence and indicates IVIG should not be used for those situations.

History notes indicate that aplastic anemias were removed from the Conditions Not Recommended for Approval list, reflecting a change in prior NMN status noted in the policy history.

Products, Codes, and Dose Thresholds

Prior Authorization, Documentation, and Prescriber Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for intravenous immune globulin (IVIG) products. Approvals are time-limited by indication and are provided for the duration noted in the policy. Requests for doses outside the dosing ranges or schedules established in this policy will be considered on a case-by-case basis by a clinician (for example, a Medical Director or Pharmacist) and may be denied.

PA required for IVIG products; approvals granted when clinical criteria and dosing are met
Requests for doses outside policy considered case-by-case by clinician; potential denial
Approvals are for the duration specified by indication (months counted as 30 days)

Documentation Required

Documentation Requirements

Documentation to support requests for IVIG must include the diagnosis and relevant clinical information to justify therapy. Include laboratory evidence where applicable (for example, age-adjusted pretreatment IgG levels, IgG trough levels, CK for myositis, antibody testing for MOG or AQP4, and genetic/molecular testing when used to confirm a primary immunodeficiency). For conditions with prior-therapy requirements, provide records of trials of systemic corticosteroids and/or immunosuppressive agents and the prescriber's statement if these are contraindicated.

Background and Scope

Intravenous immune globulin (IVIG) products are concentrated preparations of pooled human immunoglobulin G (IgG) derived from plasma donors. They are used both for replacement therapy in primary humoral immunodeficiencies and for immune modulation in a variety of autoimmune, neurologic, hematologic, transplant‑related, and infectious prophylaxis contexts.

Definitions and Clinical Thresholds

inv-51: IVIG (Immune globulin intravenous) — definition and use

DefinitionImmune globulin intravenous (IVIG) are concentrated human immunoglobulin G (IgG) preparations derived from pooled plasma used for replacement therapy in primary immunodeficiencies and for immunomodulatory effects in various autoimmune, neurologic, hematologic, and transplant‑related conditions

Primary usesReplacement therapy for primary humoral immune deficiencies and selected FDA‑approved and supportive off‑label indications (e.g., ITP, Kawasaki, CIDP)

Product noteMost listed products are FDA‑approved for replacement; formulations and administration routes (IV or SC) vary by product

inv-52: Hypogammaglobulinemia threshold for HCT recipients — serum IgG ≤ 400 mg/dL

Hypogammaglobulinemia threshold (HCT recipients)Serum IgG ≤ 400 mg/dL

Timing

Policy Revision History

2024-11-06annual_revisionLatest

Added Aquaporin-4 IgG–positive NMOSD, immune-mediated necrotizing myopathy, and MOGAD as conditions of approval; clarified molecular testing is a type of genetic testing; removed chronic fatigue syndrome from conditions not recommended for approval; added grip strength as an example of improvement for CIDP.

2024-07-24product_addition

Yimmugo was added to the policy with the same criteria as other immune globulin products.

2024-04-10

Policy Summary

PayerCareSource

PolicyIntravenous Immune Globulin (IVIG) utilization

Policy CodePolicy N/A

Change TypeAnnual revision with added indications and dosing updates

Effective DateNov 6, 2024

Next Review DateNov 6, 2024

SourceLink

On This Page

Documentation Required

Primary Immunodeficiency — Documentation and Prescriber

Primary immunodeficiency requests must include diagnostic support and laboratory evidence. Approvals for initial therapy are typically for one year when criteria are met. Documentation should include pretreatment IgG level (age-adjusted and according to the reporting laboratory), evidence of impaired antibody response or recurrent/severe infections, and genetic/molecular testing results when used to confirm the diagnosis.

Pretreatment IgG level below normal range (age-adjusted) documented
Evidence of impaired antibody response (failure to produce antibodies to specific antigens) or recurrent/severe infections
Genetic/molecular testing results when applicable
Medication prescribed by or in consultation with allergist, immunologist, ENT, pulmonologist, or infectious disease physician

Documentation Required

Product Switch Documentation

When switching IVIG products after a prior approval, the original indication and dosing must match the new request. If the client is participating in the IVIG product management program and the switch is to a preferred product, a new clinical review may not be required. If the indication or dosing differs from the originally approved request, a new clinical review is required. The new approval, if granted without additional review, should only be for the remaining doses and duration from the original approval.

Product switch allowed without new clinical review only if indication and dosing match the original approval
If indication or dosing differs, submit full clinical documentation for new review
If approved as a switch without review, approval limited to remaining previously authorized doses/duration
Preferred-product switches under IVIG product management program may not require new clinical review

Prior Authorization

Specialist Involvement Required

Specialist involvement is required for many indications. Some approvals require the medication to be prescribed by or in consultation with a specialist experienced in the condition (examples include neurologist, immunologist, hematologist/oncologist, infectious disease physician, rheumatologist, or allergist). Ensure the prescriber's specialty and consultation notes are included when required.

Many indications require prescribing by or consultation with a relevant specialist
Include specialist's name, specialty, and consultation notes when applicable
Examples: neurologist for CIDP, immunologist for primary immunodeficiency, hematologist/oncologist for post-HCT or CAR-T–related indications

Step Therapy

Prior Therapy Requirements for Autoimmune/Neuroimmunologic Indications

For multiple autoimmune and neuroimmunologic indications, prior trials of first-line therapies are required unless contraindicated. Provide documentation of trials and responses to systemic corticosteroids, plasma exchange, and/or immunosuppressive agents as specified by the indication. Lack of required prior therapy documentation or failure to meet updated clinical criteria may result in denial.

Document trials of systemic corticosteroids and/or immunosuppressive agents when required (or document contraindication)
Document trial of plasma exchange where specified (e.g., MS relapses)
Requests lacking documentation of prior therapies or not meeting updated clinical criteria may be denied

Denial Risk

Denial Risk — Insufficient Documentation or Noncovered Indications

Requests that do not meet the listed diagnosis-specific criteria (including required laboratory thresholds, documented prior therapy trials, infection status for certain hematologic/oncologic indications, or specialist-prescribing requirements) may be denied as not medically necessary. Conditions listed in the 'CONDITIONS NOT RECOMMENDED FOR APPROVAL' section will be denied.

Denial risk if required labs, prior therapies, or specialist consultation not provided
Denial for indications explicitly listed as not recommended for approval
Requests not meeting updated clinical criteria or lacking documentation (prior therapy, infection status, response) may be denied

inv-53: Impaired antibody response / functional antibody deficiency — definition and diagnostic approach

DefinitionImpaired antibody response (functional antibody deficiency) is failure to produce antibodies to specific antigens demonstrated by poor specific antibody titers or failure to respond to vaccination testing

Diagnostic approachDocumented by pre- and post-vaccination antibody measurements or clinical history of recurrent infections when testing is impractical per prescriber

Role in coverageRequired for initial IVIG therapy in many primary immunodeficiency pathways alongside low pretreatment IgG